Aerotek’s clients gain increased access to qualified candidates for their positions with the company's acquisition of Kforce’ scientific division.
Aerotek Scientific® LLC, a subsidiary of Aerotek, Inc., is excited to announce the acquisition of the scientific division of Kforce. Aerotek (www.aerotek.com) is a leading provider of technical, professional and industrial recruiting and staffing. Financial details of the acquisition have not been disclosed by company officials.
Aerotek acquired the employees, clients, contractors, and relevant data of the scientific division of Kforce. Staff previously employed by the scientific division of Kforce will continue to service their clients and contractors while working for Aerotek Scientific.
Aerotek Scientific places candidates of all levels at a variety of companies in many industries including: pharmaceuticals, biotechnology, healthcare, food & beverage, clinical research, chemical and plastics. The scientific division of Kforce’s similar focus on these markets complements Aerotek’s existing structure and will expand the company throughout the scientific industry. Kforce will retain the recruitment services that apply to the clinical trials industry.
“The acquisition of the scientific division of Kforce strengthens the presence of Aerotek Scientific within niche scientific industries nationwide,” said Thomas M. Thornton, president and chief executive officer of Aerotek. In addition to the internal growth from which our company will benefit, former Kforce Scientific and existing Aerotek clients now have access to a larger pool of qualified candidates for their positions, and contract employees have significantly more jobs available to them through our services.”
As technologies evolve and new career specialties emerge, the market for scientific professionals has continued to increase. The demand for qualified, experienced talent in scientific industries has become progressively competitive. The acquisition of the scientific division of Kforce bolsters Aerotek’s collective expertise and reinforces the company’s position as a leader in this marketplace.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.